• Home
  • F.I.S. Fabbrica Italiana Sintetici S.p.A.

F.I.S. Fabbrica Italiana Sintetici S.p.A.

About F.I.S. Fabbrica Italiana Sintetici S.p.A.

FIS is one of the CDMO leaders in Europe for small molecule APIs & Intermediates, driving innovation in drug development and production

Founded in 1957 in Montecchio Maggiore (VI) and now controlled by the private equity fund Bain Capital, FIS has been partnering with the world's leading pharmaceutical companies for 70 years in the development and production of active pharmaceutical ingredients (APIs). With over 2,300 employees in Italy across three sites, offices in North America and Japan and an operational pres...

Read more Show less
Certifications
  • FDA
    FDA
  • GMP
    GMP
  • ISO
    ISO
More certifications Show less
Sales Markets
Show more Show less
Categories
more categories Show less
  • Country/Region:
    Italy
  • Founded:
    1957
  • On CPHI since:
    2015
  • Certificates:
    3
  • Employees:
    1000 - 4999
Company types
Manufacturer/Innovator
Primary activities
API Producer
Contact info
  • Website
  • Viale Milano 26, 36075, Montecchio Maggiore (Vicenza), Italy
Show contact info Hide contact info
Meet us at

CPHI Americas 2026

Pennsylvania Convention Center, Philadelphia
2 Jun 2026 - 4 June 2026
View Exhibitor Profile

CPHI & PMEC China 2026

Shanghai New International Expo Center
16 Jun 2026 - 18 Jun 2026
View Exhibitor Profile

CPHI Milan 2026

Fiera Milano, Italy
6 Oct 2026 - 8 Oct 2026
View Exhibitor Profile

Products from F.I.S. Fabbrica Italiana Sintetici S.p.A. (27)

  • Apixaban

    Product Apixaban


  • Nitrofurantoin macrocrustals and monohydrate

    Product Nitrofurantoin macrocrustals and monohydrate

    FIS produces a wide range of API's which includes Nitrofurantoin macrocrystals and monohydrate. It is commercially available. Contact us for more information:[email protected]
  • Diazepam

    Product Diazepam

    FIS produces a wide range of API's which includes Diazepam. It is commercially available. Contact us for more information:[email protected]
  • Furosemide

    Product Furosemide

    FIS produces a wide range of API's which includes Furosemide. It is commercially available. Contact us for more information:[email protected]
  • Bromazepam

    Product Bromazepam

    FIS produces a wide range of API's which includes Bromazepam. It is commercially available. Contact us for more information:
    [email protected]
  • Chlordiazepoxide Base

    Product Chlordiazepoxide Base

    FIS produces a wide range of API's which includes Chlordiazepoxide Base. It is commercially available. Contact us for more information:[email protected]
  • Clomiphene Citrate

    Product Clomiphene Citrate

    FIS produces a wide range of API's which includes Clomiphene Citrate. It is commercially available. Contact us for more information.
  • Clonazepam

    Product Clonazepam

    FIS produces a wide range of API's which includes Clonazepam. It is commercially available. Contact us for more information.
  • Clotrimazole

    Product Clotrimazole

    FIS produces a wide range of API's which includes Clotrimazole. It is commercially available. Contact us for more information.
  • Delorazepam

    Product Delorazepam

    FIS produces a wide range of API's which includes Delorazepam. It is commercially available. Contact us for more information.
  • Eletriptan Hydrobromide

    Product Eletriptan Hydrobromide

    FIS produces a wide range of API's, which includes Eletriptan Hydrobromide. Contact us for more information.
  • Estazolam

    Product Estazolam

    FIS produces a wide range of API's which includes Estazolam. It is commercially available. Contact us for more information.
show all 27 products

F.I.S. Fabbrica Italiana Sintetici S.p.A. Resources (3)

  • Revenues up 20% in 2022

    News Revenues up 20% in 2022

    The growth trend remains in the first quarter of 2023: revenues of €153 million, up 31% compared to the first quarter of 2022
    20 Jul 2023
  • FIS joins Energize

    News FIS joins Energize

    Energize is the international programme discussed at COP27 that aims to promote the use of renewable energy and to reduce greenhouse gas emissions in the chemical and pharmaceutical sector.
    20 Jul 2023
  • FIS redefines the structure of its commercial department

    News FIS redefines the structure of its commercial department

    Luca Parlanti and Gianluca Schiavoni join FIS as directors of the new generics and custom divisions
    20 Jul 2023